Revelation Biosciences Q2 net loss $2.4M; cash $5.2M; Gemini data due Q3

REVELATION BIOSCIENCES, INC.

2025-Q2 EPS reported -$13.60

Net loss for Q2 2025 was $2.4M ($7.01 per share), improved from $8.4M ($246.27) in Q2 2024.
Cash and equivalents $5.2M at June 30, 2025, down from $6.5M at Dec 31, 2024; funds operations through Dec 2025.
Completed dosing in Phase 1b Gemini study in CKD; topline data expected later Q3 2025.
Raised $4M gross proceeds from public offering in May 2025.
Cash used in operations was $4.7M in Q2 2025 vs. $5.3M in Q2 2024.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.